Skip to main content

Market Overview

Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm

  • Celsion Corporation (NASDAQ: CLSNreports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer.
  • GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy.
  • The OVATION 2 study combines GEN-1 with standard-of-care neoadjuvant chemotherapy. NACT is designed to shrink cancer as much as possible for optimal surgical removal after three chemotherapy cycles.
  • Celsion has enrolled 34 of the anticipated 110 patients, from which 20 are in the treatment arm and 14 are in control.
  • 12 of 15 patients treated with GEN-1 had an R0 resection, which indicates a microscopically margin-negative complete resection in which no gross or microscopic tumor remains in the tumor bed.
  • 7 of 12 patients in the control arm had an R0 resection.
  • Enrollment in the study to complete during the second half of 2021.
  • Earlier this week, CLSN stock rallied after GEN-1 received Fast Track Designation for advanced ovarian cancer.
  • Price Action: CLSN at up 1.23% at $2.33 in market trading hours on the last check Thursday.

Related Articles (CLSN)

View Comments and Join the Discussion!

Posted-In: Ovarian Cancer Phase 2 TrialBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at